Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in Severe COVID-19
NCT04771000Phase 2Terminated
- Sponsor
- Noorik Biopharmaceuticals AG
- Start
- Feb 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ambrisentan in coronavirus disease 2019 (COVID-19), sponsored by Noorik Biopharmaceuticals AG. Started Feb 2021; status: terminated.
02
Drugs
ambrisentan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04771000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771000.